帕妥珠单抗和曲妥珠单抗联合治疗HER2阳性乳腺癌的效果及对患者CA125、CEA表达及生存质量的影响  

The Effect of Combination of Patuzumab and Trastuzumab on HER2 Positive Breast Cancer and the Expression of CA125,CEA and Quality of Life in Patients

作　　者：刘玲[1] LIU Ling(Puyang People's Hospital,Puyang,457000)

机构地区：[1]河南省濮阳市人民医院,457000

出　　处：《实用癌症杂志》2025年第2期255-257,共3页The Practical Journal of Cancer

摘　　要：目的 分析帕妥珠单抗联合曲妥珠单抗治疗人类表皮生长受体因子-2(HER2)阳性乳腺癌患者的效果。方法 选择98例HER2阳性乳腺癌患者,将其随机分为对照组(49例,行曲妥珠单抗治疗)、观察组(49例,加以帕妥珠单抗治疗)。对比2组临床疗效、肿瘤标志物水平、生存质量、不良反应。结果 观察组治疗总有效率高于对照组(P<0.05)。治疗后观察组糖类抗原125(CA125)为(36.53±2.67)U/mL、癌胚抗原(CEA)为(5.71±0.69)μg/L,低于对照组的(43.46±3.95)U/mL、(7.50±1.26)μg/L,差异有统计学意义(P<0.05)。治疗后观察组生命质量测定量表(FACT-B)各维度评分高于对照组(P<0.05)。2组不良反应相当(P>0.05)。结论 帕妥珠单抗联合曲妥珠单抗能够提高对HER2阳性乳腺癌的治疗效果,降低患者肿瘤标志物水平,提高生存质量,且无严重不良反应,值得临床借鉴。Objective To analyze the effect of patuzumab combined with trastuzumab in the treatment of human epidermal growth receptor factor-2(HER2)positive breast cancer patients.Methods 98 patients with HER2 positive breast cancer were randomly divided into the control group(49 cases,treated with trastuzumab)and the observation group(49 cases,treated with pertuzumab).Compare the clinical efficacy,tumor marker levels,quality of life,and adverse reactions between the 2 groups.Results The total effective rate of the observation group was higher than the control group(P<0.05).The post-treatment carbohydrate antigen 125(CA125)was(36.53±2.67)U/mL and carcinoembryonic antigen(CEA)was(5.71±0.69)μg/L in the observation group,which were lower than the control group,(43.46±3.95)U/mL and(7.50±1.26)μg/L,there had statistical difference(P<0.05).After treatment,the quality of life measurement scale(FACT-B)scores in each dimension of the observation group were higher than those of the control group(P<0.05).The 2 groups had comparable adverse reactions(P>0.05).Conclusion Patuzumab combined with trastuzumab can improve the therapeutic effect of HER2 positive breast cancer,reduce the level of tumor markers,improve the quality of life,and have no serious adverse reactions,which is worthy of clinical reference.

关 键 词：乳腺癌 人类表皮生长受体因子-2 阳性 生存质量 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]